Patents by Inventor Jeffrey Gilbert Varnes

Jeffrey Gilbert Varnes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10149839
    Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: December 11, 2018
    Assignee: AstraZeneca AB
    Inventors: James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam, Dan Anders Broo, Bin Yang, Jeffrey Gilbert Varnes, Dedong Wu
  • Patent number: 10125135
    Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: November 13, 2018
    Assignee: AstraZeneca AB
    Inventors: Bin Yang, Jeffrey Gilbert Varnes, James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam
  • Publication number: 20180021316
    Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: July 24, 2017
    Publication date: January 25, 2018
    Inventors: James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam, Dan Anders Broo, Bin Yang, Jeffrey Gilbert Varnes, Dedong Wu
  • Publication number: 20170305909
    Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: April 19, 2017
    Publication date: October 26, 2017
    Inventors: Bin YANG, Jeffrey Gilbert VARNES, James Stewart SCOTT, Thomas Andrew MOSS, Daniel Hillebrand O'DONOVAN, Johannes Wilhelmus Maria NISSINK, Samantha Jayne HUGHES, Bernard Christophe BARLAAM
  • Publication number: 20160176906
    Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 23, 2016
    Applicant: AstraZeneca AB
    Inventors: Robert Bruce Diebold, Thomas Woodrow Gero, Paul Grover, Shan Huang, Stephanos Ioannidis, Claude Afona Ogoe, Jamal Carlos Saeh, Jeffrey Gilbert VARNES
  • Publication number: 20150328239
    Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.
    Type: Application
    Filed: February 18, 2015
    Publication date: November 19, 2015
    Applicant: AstraZeneca AB
    Inventors: Robert Bruce Diebold, Thomas Woodrow Gero, Paul Grover, Shan Huang, Stephanos Ioannidis, Claude Afona Ogoe, Jamal Carlos Saeh, Jeffrey Gilbert VARNES
  • Publication number: 20130310344
    Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.
    Type: Application
    Filed: August 5, 2011
    Publication date: November 21, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Robert Bruce Diebold, Thomas Gero, Paul Grover, Shan Huang, Stephanos Ioannidis, Claude Afona Ogoe, Jamal Carlos Saeh, Jeffrey Gilbert Varnes
  • Publication number: 20120094995
    Abstract: This invention relates to 2-aza-bicyclo[2.2.1]heptane compounds (and salts thereof), the process for making such a compound and pharmaceutical compositions comprising such a compound. The invention also relates to the use of the compounds for modulating the glycine transporter 1 (GlyT1) and for the treatment of psychosis, cognitive disorders, bipolar disorders, depression disorders, anxiety disorders, post-traumatic stress disorders and pain.
    Type: Application
    Filed: January 27, 2010
    Publication date: April 19, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Jeffrey Scott Albert, Donald Andisik, Cristobal Alhambra, Todd Andrew Brugel, Glen E Ernst, William Frietze, Lindsay Hinkley, Jeffrey Gilbert Varnes, Xia Wang, Hui Xiong
  • Publication number: 20120035134
    Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.
    Type: Application
    Filed: August 5, 2011
    Publication date: February 9, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Robert Bruce DIEBOLD, Thomas GERO, Paul GROVER, Shan HUANG, Stephanos IOANNIDIS, Claude Afona OGOE, Jamal Carlos SAEH, Jeffrey Gilbert VARNES
  • Publication number: 20090030033
    Abstract: The invention relates to 2-aza-bicyclo[2.2.2]octane compounds and uses thereof. Particularly the invention relates to such compounds and their uses as pharmaceuticals in treating pyshoses such as schizophrenia and other diseases, disorders, or conditions.
    Type: Application
    Filed: July 22, 2008
    Publication date: January 29, 2009
    Applicant: AstraZeneca AB
    Inventors: Jeffrey Scott Albert, Cristobal Alhambra, Todd Andrew Brugel, Jeffrey Gilbert Varnes